Bal Pharma Balance Sheet Health

Financial Health criteria checks 2/6

Bal Pharma has a total shareholder equity of ₹687.6M and total debt of ₹1.5B, which brings its debt-to-equity ratio to 225.4%. Its total assets and total liabilities are ₹3.4B and ₹2.7B respectively. Bal Pharma's EBIT is ₹224.8M making its interest coverage ratio 1.8. It has cash and short-term investments of ₹247.2M.

Key information

225.4%

Debt to equity ratio

₹1.55b

Debt

Interest coverage ratio1.8x
Cash₹247.15m
Equity₹687.58m
Total liabilities₹2.71b
Total assets₹3.40b

Recent financial health updates

Recent updates

Here's Why Shareholders May Want To Be Cautious With Increasing Bal Pharma Limited's (NSE:BALPHARMA) CEO Pay Packet

Sep 19
Here's Why Shareholders May Want To Be Cautious With Increasing Bal Pharma Limited's (NSE:BALPHARMA) CEO Pay Packet

Bal Pharma (NSE:BALPHARMA) Is Increasing Its Dividend To ₹1.20

Aug 31
Bal Pharma (NSE:BALPHARMA) Is Increasing Its Dividend To ₹1.20

Bal Pharma Limited's (NSE:BALPHARMA) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

Aug 27
Bal Pharma Limited's (NSE:BALPHARMA) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

Bal Pharma (NSE:BALPHARMA) Is Paying Out A Larger Dividend Than Last Year

Aug 15
Bal Pharma (NSE:BALPHARMA) Is Paying Out A Larger Dividend Than Last Year

Insufficient Growth At Bal Pharma Limited (NSE:BALPHARMA) Hampers Share Price

May 30
Insufficient Growth At Bal Pharma Limited (NSE:BALPHARMA) Hampers Share Price

Does Bal Pharma (NSE:BALPHARMA) Have A Healthy Balance Sheet?

Mar 14
Does Bal Pharma (NSE:BALPHARMA) Have A Healthy Balance Sheet?

Bal Pharma Limited's (NSE:BALPHARMA) 26% Share Price Surge Not Quite Adding Up

Feb 01
Bal Pharma Limited's (NSE:BALPHARMA) 26% Share Price Surge Not Quite Adding Up

Bal Pharma Limited's (NSE:BALPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment

Sep 18
Bal Pharma Limited's (NSE:BALPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment

Bal Pharma (NSE:BALPHARMA) Is Due To Pay A Dividend Of ₹1.00

Aug 28
Bal Pharma (NSE:BALPHARMA) Is Due To Pay A Dividend Of ₹1.00

Bal Pharma (NSE:BALPHARMA) Is Paying Out A Dividend Of ₹1.00

Aug 14
Bal Pharma (NSE:BALPHARMA) Is Paying Out A Dividend Of ₹1.00

Bal Pharma (NSE:BALPHARMA) Is Paying Out A Dividend Of ₹1.00

Aug 17
Bal Pharma (NSE:BALPHARMA) Is Paying Out A Dividend Of ₹1.00

Bal Pharma (NSE:BALPHARMA) Has Announced A Dividend Of ₹1.00

Jul 31
Bal Pharma (NSE:BALPHARMA) Has Announced A Dividend Of ₹1.00

Is Bal Pharma (NSE:BALPHARMA) Using Too Much Debt?

Mar 08
Is Bal Pharma (NSE:BALPHARMA) Using Too Much Debt?

Bal Pharma (NSE:BALPHARMA) Use Of Debt Could Be Considered Risky

Nov 23
Bal Pharma (NSE:BALPHARMA) Use Of Debt Could Be Considered Risky

Does Bal Pharma Limited (NSE:BALPHARMA) Have A Place In Your Dividend Stock Portfolio?

Aug 10
Does Bal Pharma Limited (NSE:BALPHARMA) Have A Place In Your Dividend Stock Portfolio?

Should You Buy Bal Pharma Limited (NSE:BALPHARMA) For Its 2.3% Dividend?

Aug 10
Should You Buy Bal Pharma Limited (NSE:BALPHARMA) For Its 2.3% Dividend?

Financial Position Analysis

Short Term Liabilities: BALPHARMA's short term assets (₹2.5B) exceed its short term liabilities (₹2.2B).

Long Term Liabilities: BALPHARMA's short term assets (₹2.5B) exceed its long term liabilities (₹500.4M).


Debt to Equity History and Analysis

Debt Level: BALPHARMA's net debt to equity ratio (189.4%) is considered high.

Reducing Debt: BALPHARMA's debt to equity ratio has increased from 205.1% to 225.4% over the past 5 years.

Debt Coverage: BALPHARMA's debt is not well covered by operating cash flow (19.6%).

Interest Coverage: BALPHARMA's interest payments on its debt are not well covered by EBIT (1.8x coverage).


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 01:51
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bal Pharma Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution